Elsevier and eMolecules Collaboration Enables Easy Sourcing of Chemicals via Reaxys(R)

FRANKFURT, September 14, 2010 /PRNewswire/ --

- Enriched Content Offering Integrates Reaction and Substance Searching, Synthesis Planning and Chemical Procurement Into a Seamless Workflow

Elsevier is pleased to announce that Reaxys now provides an enriched commercial availability service, as a result of the ongoing collaboration between the Reaxys development team and eMolecules. Chemical procurement of commercially available compounds is now incorporated into the reaction and substance search workflow. Research chemists can now immediately access the eMolecules ordering page, complete with full quantity, pricing and vendor information, all via the eMolecules icon. It becomes part of the overall research workflow, the chemist can order the desired compound and easily continue with their reaction or substance query.

Reaxys is Elsevier's web-based chemistry application which combines reaction and substance data search and retrieval in organic, organometallic, inorganic and physical chemistry with synthesis planning. Reaxys allows research chemists to get important and relevant information from journals and patents fast and conveniently in a single overview.

Mark van Mierle, MD of Elsevier Information Systems, said, "Sourcing the right chemical at the best price and in an easy manner is clearly a crucial step in a chemist's workflow. I believe this enhancement to Reaxys will enable chemists to make better decisions and get back to the lab more quickly."

Klaus Gubernator, CEO, eMolecules, added, "The collaboration between Elsevier and eMolecules focuses on providing our customers with an enhanced user experience, and the incorporation of all elements of the chemist's workflow into one integrated system."

The Reaxys development team will continue to work with eMolecules to further streamline all aspects of the commercial availability process in order to bring the researchers the most relevant information with fewer clicks.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com) and Cell (http://www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (http://www.sciencedirect.com), Scopus (http://www.scopus.com), Reaxys (http://www.reaxys.com), MD Consult (http://www.mdconsult.com) and Nursing Consult (http://www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com) and MEDai's Pinpoint Review (http://www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (http://www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (http://www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About eMolecules

eMolecules is the world's leading open-access chemical structure search engine, providing chemistry eCommerce solutions for suppliers of research chemicals and industrial and academic research organizations. They deliver chemical building blocks and screening compounds worldwide from any supplier in any requested physical format. They are the most popular chemistry web site, distinguished by fast results, ease of use, and up to date information about commercially available chemicals.

About Elsevier Properties SA

Elsevier Properties SA is a center of excellence within Reed Elsevier for the management of intellectual property. Elsevier Properties SA owns the PharmaPendium, Beilstein and Reaxys databases. Trademarks including Reaxys(R), PharmaPendium(TM), SciVal(TM) and The Lancet(R) are owned and protected by Elsevier Properties SA and used under license. For additional information see http://www.reedelsevier.com.

    Media Contact
    Tom Reller
    Vice President, Global Corporate Relations
    +1-215-239-3508
    [email protected]

SOURCE Elsevier and Elsevier Properties

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED